WO2020139866A3 - Compositions and methods for treating cancer - Google Patents

Compositions and methods for treating cancer Download PDF

Info

Publication number
WO2020139866A3
WO2020139866A3 PCT/US2019/068423 US2019068423W WO2020139866A3 WO 2020139866 A3 WO2020139866 A3 WO 2020139866A3 US 2019068423 W US2019068423 W US 2019068423W WO 2020139866 A3 WO2020139866 A3 WO 2020139866A3
Authority
WO
WIPO (PCT)
Prior art keywords
dsrna
sense strand
antisense strand
compositions
methods
Prior art date
Application number
PCT/US2019/068423
Other languages
French (fr)
Other versions
WO2020139866A2 (en
Inventor
Vivienne I. Rebel
David J. ELZI
William E. Bauta
Original Assignee
Bioaffinity Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioaffinity Technologies, Inc. filed Critical Bioaffinity Technologies, Inc.
Priority to EP19904756.4A priority Critical patent/EP3902917A4/en
Priority to CN201980093039.3A priority patent/CN113508175A/en
Priority to CA3163139A priority patent/CA3163139A1/en
Publication of WO2020139866A2 publication Critical patent/WO2020139866A2/en
Publication of WO2020139866A3 publication Critical patent/WO2020139866A3/en
Priority to US17/359,905 priority patent/US20230035774A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

A double stranded RNA interference (RNAi) agent comprising at least one of (i) a first double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a CD320 gene wherein the first dsRNA comprises a sense strand and an antisense strand forming a duplex, (ii) a second dsRNA for inhibiting the expression of a LRP2 gene wherein the second dsRNA comprises a sense strand and an antisense strand forming a duplex, or (iii) a cocktail of (i) and (ii) and wherein the sense strand of the first dsRNA is at least substantially complementary to the antisense strand of the first dsRNA and the sense strand of the second dsRNA is at least substantially complementary to the antisense strand of the second dsRNA and the use of the RNAi agent as a pharmaceutical composition for the treatment of cancer in subjects in need of treatment.
PCT/US2019/068423 2018-12-27 2019-12-23 Compositions and methods for treating cancer WO2020139866A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP19904756.4A EP3902917A4 (en) 2018-12-27 2019-12-23 Compositions and methods for treating cancer
CN201980093039.3A CN113508175A (en) 2018-12-27 2019-12-23 Compositions and methods for treating cancer
CA3163139A CA3163139A1 (en) 2018-12-27 2019-12-23 Compositions and methods for treating cancer
US17/359,905 US20230035774A1 (en) 2018-12-27 2021-06-28 Compositions and Methods for Treating Cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785592P 2018-12-27 2018-12-27
US62/785,592 2018-12-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/359,905 Continuation-In-Part US20230035774A1 (en) 2018-12-27 2021-06-28 Compositions and Methods for Treating Cancer

Publications (2)

Publication Number Publication Date
WO2020139866A2 WO2020139866A2 (en) 2020-07-02
WO2020139866A3 true WO2020139866A3 (en) 2020-10-15

Family

ID=71129313

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/068423 WO2020139866A2 (en) 2018-12-27 2019-12-23 Compositions and methods for treating cancer

Country Status (4)

Country Link
EP (1) EP3902917A4 (en)
CN (1) CN113508175A (en)
CA (1) CA3163139A1 (en)
WO (1) WO2020139866A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023277959A1 (en) * 2021-06-28 2023-01-05 Bioaffinity Technologies, Inc. Compositions and methods for treating cancer

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239270B1 (en) * 1993-05-24 2001-05-29 Rhone-Poulenc Rorer S.A. Nucleic acids encoding human calcium sensor protein
US20030004311A1 (en) * 1997-06-18 2003-01-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060234260A1 (en) * 1997-11-28 2006-10-19 Serono Genetics Institute S.A. Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
WO2007140506A1 (en) * 2006-06-02 2007-12-13 Human Genetic Signatures Pty Ltd Modified microbial nucleic acid for use in detection and analysis of microorganisms
US20080050393A1 (en) * 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
WO2008116171A1 (en) * 2007-03-21 2008-09-25 Raptor Pharmaceutical Inc. Cyclic receptor-associated protein (rap) peptides
US20110195523A1 (en) * 2006-03-28 2011-08-11 Niigata University Method for measuring human megalin
US20140068793A1 (en) * 2006-04-07 2014-03-06 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
WO2017223273A1 (en) * 2016-06-22 2017-12-28 President And Fellows Of Harvard College Inhibition of colonic group 3 innate lymphoid cells
US10113201B2 (en) * 2013-04-05 2018-10-30 The Wistar Institute Of Anatomy And Biology Methods and compositions for diagnosis of glioblastoma or a subtype thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053455A2 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
EP2010226B1 (en) * 2006-04-07 2014-01-15 The Research Foundation of State University of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
ES2964607T3 (en) * 2015-07-17 2024-04-08 Pacylex Pharmaceuticals Inc Epigenetic silencing of NMT2

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239270B1 (en) * 1993-05-24 2001-05-29 Rhone-Poulenc Rorer S.A. Nucleic acids encoding human calcium sensor protein
US20030004311A1 (en) * 1997-06-18 2003-01-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060234260A1 (en) * 1997-11-28 2006-10-19 Serono Genetics Institute S.A. Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US20080050393A1 (en) * 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
US20110195523A1 (en) * 2006-03-28 2011-08-11 Niigata University Method for measuring human megalin
US20140068793A1 (en) * 2006-04-07 2014-03-06 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9044461B2 (en) * 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
WO2007140506A1 (en) * 2006-06-02 2007-12-13 Human Genetic Signatures Pty Ltd Modified microbial nucleic acid for use in detection and analysis of microorganisms
WO2008116171A1 (en) * 2007-03-21 2008-09-25 Raptor Pharmaceutical Inc. Cyclic receptor-associated protein (rap) peptides
US10113201B2 (en) * 2013-04-05 2018-10-30 The Wistar Institute Of Anatomy And Biology Methods and compositions for diagnosis of glioblastoma or a subtype thereof
WO2017223273A1 (en) * 2016-06-22 2017-12-28 President And Fellows Of Harvard College Inhibition of colonic group 3 innate lymphoid cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 26 December 2017 (2017-12-26), "PREDICTED: Seriola lalandi dorsalis pleckstrin -homology and RhoGEF domain containing G3 (plekhg3), mRNA; Publication", Database accession no. XM 023408803.1 *
LEARY, M ET AL.: "Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy", CANCERS, vol. 10, no. 483, 4 December 2018 (2018-12-04), pages 1 - 18, XP055747657 *
SILVIA MONTEAGUDO, FRANCISCO C PÉREZ-MARTÍNEZ, MARÍA D PÉREZ-CARRIÓN, JAVIER GUERRA, SONIA MERINO, MARÍA PRADO SÁNCHEZ-VERDÚ , VAL: "Inhibition of p42 MAPK using a nonviral vector-delivered siRNA - potentiates the anti-tumor effect of meformin in prostate cancer cells", NANOMEDICINE, vol. 7, no. 4, 1 April 2012 (2012-04-01), pages 493 - 506, XP055824058, ISSN: 1743-1559, DOI: 10.2217/nnm.11.61 *

Also Published As

Publication number Publication date
EP3902917A2 (en) 2021-11-03
EP3902917A4 (en) 2022-11-30
CN113508175A (en) 2021-10-15
CA3163139A1 (en) 2020-07-02
WO2020139866A2 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
WO2004083430A3 (en) SHORT INTERFERING RNA (siRNA) ANALOGUES
BR112016013148A2 (en) "Complement component component compositions and methods of using them
WO2007134161A8 (en) Compositions and methods for inhibiting expression of the pcsk9 gene
WO2008109450A3 (en) Nucleic acid compounds for inhibiting id-1 gene expression and uses thereof
WO2007022369A8 (en) Chemically modified short interfering nucleic acid molecules that mediate rna interference
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
WO2003070970A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA)
WO2007084865A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2011008730A3 (en) Chemical modification of small hairpin rnas for inhibition of gene expression
WO2007128477A3 (en) SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION
WO2005040379A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF RAS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2008049078B1 (en) Nicked or gapped nucleic acid molecules and uses thereof
WO2007076328A3 (en) Rna interference mediated inhibition of hepatitis c virus
WO2008008719A3 (en) Compositions and methods for inhibiting expression of the myc gene
WO2004092383A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2005045037A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2019217397A3 (en) Compositions and methods for improving strand biased
WO2003070887A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
WO2020139866A3 (en) Compositions and methods for treating cancer
WO2005007855A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2011139843A3 (en) Multi-sirna compositions for reducing gene expression
WO2010017311A3 (en) Nucleic acid compounds for inhibiting birc5 gene expression and uses thereof
WO2009104896A3 (en) Nucleic-acid pharmaceutical composition for cancer therapy
WO2005045036A3 (en) Rna interference mediated inhibition of hairless (hr) gene expression using short interfering nucleic acid (sina)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19904756

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019904756

Country of ref document: EP

Effective date: 20210727

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19904756

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3163139

Country of ref document: CA